NCI Opens New Immunotherapy Clinical Trial for Mesothelioma
Research & Clinical Trials
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
Testimonials
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
APA
Povtak, T. (2022, March 29). NCI Opens New Immunotherapy Clinical Trial for Mesothelioma. Asbestos.com. Retrieved March 23, 2023, from https://www.asbestos.com/news/2022/01/04/nci-immunotherapy-mesothelioma-trial/
MLA
Povtak, Tim. "NCI Opens New Immunotherapy Clinical Trial for Mesothelioma." Asbestos.com, 29 Mar 2022, https://www.asbestos.com/news/2022/01/04/nci-immunotherapy-mesothelioma-trial/.
Chicago
Povtak, Tim. "NCI Opens New Immunotherapy Clinical Trial for Mesothelioma." Asbestos.com. Last modified March 29, 2022. https://www.asbestos.com/news/2022/01/04/nci-immunotherapy-mesothelioma-trial/.
The National Cancer Institute has opened a promising clinical trial aimed at increasing the effectiveness of immunotherapy treatment for patients with unresectable malignant mesothelioma.
This latest study involves combining LMB-100, a manmade protein designed to kill cancer cells, with ipilimumab, an immunotherapy drug recently approved for use by the U.S. Food and Drug Administration. Ipilimumab is also known by the brand name Yervoy.
Although immunotherapy has worked well with some cancers, its effectiveness in treating mesothelioma has been selective and has lacked sustainability.
This new study combination has been especially effective in earlier laboratory testing, leading to the phase I clinical trial for both pleural and peritoneal mesothelioma.
“We know it works in mice,” principal investigator Dr. Raffit Hassan told The Mesothelioma Center at Asbestos.com. “Whether it works in humans, only time will tell. We’ll have to see. The goal is making these tumors more responsive to immunotherapy.”
Hassan is chief of the Thoracic and GI Malignancies Branch at the National Institutes of Health Clinical Center in Bethesda, Maryland, where the trial has begun. He has been instrumental in recent mesothelioma treatment advances.
Combination Could Offer Viable Second-Line Option
The trial is designed for patients with inoperable disease, where both standard chemotherapy and immunotherapy were used earlier before tumor growth returned. It is for confirmed cases of epithelial or biphasic mesothelioma, the most common types of mesothelioma.
“For patients today, there really is no, or very limited, options after chemotherapy and immunotherapy have failed,” Hassan said. “This study offers a reasonable chance of benefit. It would be nice to see if these patients again respond to immunotherapy.”
The FDA approved Opdivo and Yervoy, an immunotherapy combination, for first-line treatment of pleural mesothelioma in 2020. It was the first new systemic approval in more than 16 years. However, it only increased the median overall survival time from 14.1 months to 18.1 months, when compared to standard chemotherapy.
LMB-100 Trial Follows Earlier Study
This latest mesothelioma trial is building on an earlier study at the National Cancer Institute involving pembrolizumab (Keytruda), another immunotherapy drug with a different way of delivering LMB-100.
The earlier trial used systemic delivery. This latest trial involves an intratumor injection of the drug, a novel method that will be watched closely for its potential to better stimulate a more durable immune system response.
LMB-100 works by targeting mesothelin, a tumor-associated antigen that is found highly expressed on the surface of many different types of tumors, including pancreatic, ovarian, lung and mesothelioma.
“In mice, you can completely get rid of the tumors with this delivery. Not only the ones injected, but those not injected,” Hassan said. “It’s one reason for this clinical trial to see if we can achieve the same in patients.”
Researchers Test Safe Dosage Levels
Patients in the trial will receive the LMB-100 injections into their tumors on days 1 and 4 for up to two 21-day cycles. Those will be combined with up to four doses of ipilimumab systemically.
Through the trial, researchers expect to identify the safest and best dosage levels for both LMB-100 and ipilimumab.
Ipilimumab is known as a checkpoint inhibitor immunotherapy, which helps the body’s immune system attack cancer cells.
LMB-100 was designed originally to broaden immunotherapy effectiveness. Dr. Ira Pastan, an NCI scientist, led the drug’s development.
“There is hope on the horizon – more options today for patients with mesothelioma than there were a few years ago,” Hassan said. “We’ll just have to see where this goes. Progress is being made.”
